Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab in recurring-persistent cervical carcinoma
NCT02083211Phase 3Completed
- Sponsor
- Instituto Nacional de Cancerología
- Start
- Jul 2010
- Primary completion
- May 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nimotuzumab in Cervical Cancer (CC), sponsored by Instituto Nacional de Cancerología. Started Jul 2010; status: completed.
02
Drugs
nimotuzumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT02083211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02083211.